

June 27, 2019

VOLUNTARY MEDICAL DEVICE PRODUCT RECALL

SPECTRA OPTIA® APHERESIS SYSTEM
Potential for Electronic Connection Intermittency

Devices Affected: Spectra Optia Apheresis Systems

Serial Numbers: 1P00828, 1P00944, 1P01073, 1P01145, 1P01241, 1P01262, 1P01427, 1P01511, 1P01632, 1P01973, 1P02343, 1P03218, 1P03937, 1P05771, 1P06015, 1P06016, 1P06017, 1P06018, 1P06019, 1P06020, 1P06021, 1P06022, 1P06023, 1P06024, 1P06025, 1P06026, 1P06027, 1P06038, 1P06039, 1P06040, 1P06043, 1P06044, 1P06045, 1P06046, 1P06052, 1P06053, 1P06054, 1P06055, 1P06056, 1P06057, 1P06059, 1P06060, 1P06061, 1P06062, 1P06063, 1P06064, 1P06065, 1P06066, 1P06067, 1P06068, 1P06069, 1P06070, 1P06071, 1P06072, 1P06074, 1P06075, 1P06076, 1P06077, 1P06078, 1P06079, 1P06080, 1P06088, 1P06089, 1P06090, 1P06091, 1P06092, 1P06093, 1P06096, 1P06099, 1P06100, 1P06101, 1P06102, 1P06103, 1P06104, 1P06106, 1P06107, 1P06108, 1P06109, 1P06110, 1P06111, 1P06112, 1P06113, 1P06114, 1P06115, 1P06116, 1P06117, 1P06118, 1P06119, 1P06120, 1P06121, 1P06122, 1P06123, 1P06124, 1P06125, 1P06126, 1P06127, 1P06128, 1P06129, 1P06130, 1P06131, 1P06132, 1P06133, 1P06134, 1P06136, 1P06137, 1P06138, 1P06139, 1P06142, 1P06147, 1P06148, 1P06151, 1P06152, 1P06156, 1P06160, 1P06185, 1P06191

Dear Valued Customer:

Terumo BCT has become aware of an unintended height deviation of the physical supports for a circuit card assembly (CCA) installed in the Spectra Optia apheresis device. Spectra Optia apheresis systems contained in the serial numbers listed above could exhibit an intermittent electronic connection due to this deviation.

REASON FOR PRODUCT RECALL

Terumo BCT has **not** received any customer reports of intermittent electronic connections that were identified to have been caused by this identified defect. Terumo BCT is issuing this recall and corrective action notice to inform users of the Spectra Optia system about this defect and to assure them that all potentially affected devices are corrected. You are being notified of this defect because our records indicate that you may have received one or more of the identified devices.

Terumo BCT, Inc.
 10811 West Collins Ave
 Lakewood, Colorado 80215-4440
 USA
 USA Phone: 1 677 339 4226
 Phone: +1 303 231 4357
 Fax: +1 303 542 5215

Terumo BCT Europe N.V.
 Europe, Middle East and Africa
 Ikarosstraat 11
 1930 Zaventem
 Belgium
 Phone: +32 2 715 0590
 Fax: +32 2 721 0770

Terumo BCT Asia Pte. Ltd.
 S9 Science Park Drive
 #04-25 (Lobby B)
 The Rutherford
 Singapore 118261
 Phone: +65 6716 3776
 Fax: +65 6774 1419

Terumo BCT Latin America S.A.
 La Pampa 1517-12^o Floor
 C1428DZE
 Buenos Aires
 Argentina
 Phone: +54 11 5530 5200
 Fax: +54 11 5530 5201

Terumo BCT Japan, Inc.
 Tokyo Opera City Tower 49F
 3-20-2, Nishi-Shinjuku
 Shinjuku-ku, Tokyo 163-1450
 Japan
 Phone: +81 3 6743 7890
 Fax: +81 3 6743 9800

RISK TO THE PATIENT

This notice advises Spectra Optia operators to observe and adhere to all system alarms and their resulting on-screen instructions by following good clinical practice.

- No unsafe system behavior has been linked to this deviation.
- All alarms contain on-screen instructions; please follow them accordingly.
- If the system presents repeated alarms across multiple procedures that do not result from a known cause, it may be necessary to end the procedure.

ACTIONS BEING TAKEN BY TERUMO BCT

- a) Terumo BCT is taking action by notifying you of this potential defect in a Spectra Optia device you have from the above identified list.
- b) In addition to this letter, Terumo BCT will arrange for inspection of all Spectra Optia apheresis systems with the CCA card assembly supports that potentially contain this identified defect. A member of Terumo BCT’s technical service team will contact you to arrange for inspection of any potentially affected devices at your facility. Any identified devices containing this defect will be corrected by replacing the housing that contains the CCA card assembly supports. Devices that are not affected will not require correction.

ACTIONS REQUIRED BY HEALTHCARE PROVIDERS AND DISTRIBUTORS

1. Distribute this notification to all Spectra Optia system users within your organization.
2. Continue to use your Spectra Optia system(s) in accordance with the operator’s manual and the operator training materials.
3. If any Spectra Optia system(s) present repeated alarms across multiple procedures that do not result from a known cause, it may be necessary to end the procedure.

IMPORTANT: Complete the attached acknowledgement and fax or email the acknowledgement to Terumo BCT by **August 9th, 2019**. Your return of the acknowledgement is critical so that we can confirm that you have received the Safety Alert.

CONTACT INFORMATION

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA in one of the following ways:

- Online: <http://www.fda.gov/Safety/MedWatch/HowtoReport/default.htm>. Complete the form provided and return it by fax or mail.
- Phone U.S. Toll-Free: 1.800.FDA.1088

Terumo BCT is dedicated to providing you with the highest quality support and communicating information regarding our products. If you have any questions, please contact your Terumo BCT representative or your regional Customer Support Center:

- U.S. Toll-Free: 1.877.3.FYI BCT (394 228)
- U.S.: +1.303. 231.HELP (4357)
- Canada Toll-Free: 1.877.722.8411

Sincerely,

A handwritten signature in black ink, appearing to read 'Cynthia A. Hougum', with a long horizontal flourish extending to the right.

Cynthia A Hougum, PhD
Senior Vice President, Global Quality Transformation

VOLUNTARY MEDICAL DEVICE PRODUCT RECALL RETURN RESPONSE
Spectra Optia System: Potential for Electronic Connection Intermittency
Acknowledgement and Receipt Form

Response Is Required

I have read and understand the recall instructions provided in the letter of June 27, 2019.

Yes ___ No ___

I have additional questions. I would like a Terumo BCT representative to contact me.

Yes ___ No ___

Are there any adverse events (serious injury or death) associated with electronic connection intermittency on Spectra Optia that have not been previously reported?

Yes ___ No ___

If yes, please explain:

Facility Name: (Please print) _____

Facility Address: _____

City _____ State _____ Zip Code _____

Print Name/Title: _____

Signature: _____

Telephone: _____ Email Address: _____

Please fax this completed form to 1.303.876.9277
or email it to Regulatory.Affairs@TerumoBCT.com.